[1]TrépoC,ChanHL, LokA.Hepatitis Bvirusinfection[J].Lancet.2014,384(9959): 2053.
[2]Zahn G, Greischel A. The impact of vaccination and antiviral therapy on hepatitis BandhepatitisDepidemiology.[J].PlosOne.2014,9(10):e110143.
[3]AsL. ChronichepatitisB [J].NEnglJMed.2002(346): 1682-1683.
[4]Liang X, Bi S, Yang W, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination.[J]. Vaccine. 2013,31Suppl9(47):J21.
[5]Lao T T, Sahota D S, Law LW, et al.Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China[J].BulletinoftheWorldHealthOrganization.2014,92(11):782.
[6] Zhang L,Gui X,Fan J,et al.Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus[J].JMaternFetalNeonatalMed,2014,27(2):182-186.
[7]Wen W H, Lai M W, Chang M H. A review of strategies to prevent mother-to-infant transmission of hepatitis b virus infection [J]. Expert Review of Gastroenterology&Hepatology.2016,10(3):317-330.
[8] Han L, Zhang H W, Xie J X, et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus[J]. World journal of gastroenterology: WJG, 2011, 17(38): 4321.
[9] Lao T T, Sahota DS, Cheng Y K,et al. Maternal hepatitis B surface antigen status and appearance of pre-eclampsia[J].JViral Hepat,2013,20(5):343-349.
[10]Ii J G P, Jr J M M, Summers P R. The effect of hepatitis B antigenemia on pregnancy outcome[J]. American Journal of Obstetrics & Gynecology. 1988, 158(1): 486-489.
[11] Wong S, Chan L Y, Yu V, et al. Hepatitis B carrier and perinatal outcome in singleton pregnancy[J]. American journal of perinatology, 1999, 16(09): 0485-0488.
[12] Zheng, S., Zhang, H., Chen, R. et al. Pregnancy complicated with hepatitis B virus infection and preterm birth: a retrospective cohort study. [J] BMC Pregnancy Childbirth 21, 513 (2021).
[13] Safir A, Levy A, Sikuler E, et al. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome.[J]. Liver International.2010,30(5):765-770.
[14] Wan Z, Zhou A, Zhu H et al. Maternal Hepatitis B Virus Infection and Pregnancy Outcomes: A Hospital-based Case-control Study in Wuhan, China[J]. Journal of ClinicalGastroenterology.2017,52:1.
[15] Cai Q, Liu H, Han W, et al Maternal HBsAg carriers and adverse pregnancy outcomes: A hospital-based prospective cohort analysis. [J] Viral Hepat. 2019 Aug;26(8):1011-1018.
[16] Armistead B, Johnson E, VanderKamp R, et al. Placental regulation of energy homeostasis during human pregnancy[J]. Endocrinology, 2020, 161(7): bqaa076.
[17] Luo L, Wu J, Qu Y, et al. Association between maternal HBsAg carrier status and neonatal adverse outcomes: meta-analysis[J]. The Journal of Maternal-Fetal & Neonatal Medicine, 2015, 28(11): 1308-1317.
[18] Girard S, Heazell AE, Derricott H, et al. Circulating cytokines and alarmins associated with placental inflammation in highrisk pregnancies[J]. Am J Reprod Immunol,2014,72(4):422-434
[19] Cotechini T, Komisarenko M, Sperou A, et al. Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia[J]. J Exp Med,2014,211(1):165-179.
[20] Feld JJ, Heathcote EJ. Hepatitis B e antigen- positive chronic hepatitis B: natural history and treatment[J]. Semin Liver Dis,2006,26(2):116-129.
[21] Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma[J]. World J Gastroenterol,2014,20(34):12039-12044.
[22] Chen L, Zhang Q, Chang W, et al. Viral and host inflammationrelated factors that can predict the prognosis of hepatocellularcarcinoma[J]. Eur J Cancer,2012,48(13):1977-1987.
[23] Patton H, Tran TT. Management of hepatitis B during pregnancy[J]. Nat Rev Gastroenterol Hepatol,2014,11(7):402-409.
[24]Gomes C P, Torloni M R, Gueuvoghlanian‐Silva B Y, et al. Cytokine levels in gestational diabetes mellitus: a systematic review of the literature[J]. American Journal of Reproductive Immunology, 2013, 69(6): 545-557.
[25] Shimoda T, Shikata T, Karasawa T, et al. Light microscopic localization of hepatitis B virus antigens in the human pancreas. Possibility of multiplication of hepatitis B virus in the human pancreas[J]. Gastroenterology, 1981, 81(6): 998-1005.
[26] Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009;15:2049–66.
[27] Tan J, Liu X, Mao X, et al. HBsAg positivity during pregnancy and adverse maternal outcomes: a retrospective cohort analysis[J]. Journal of viral hepatitis, 2016, 23(10): 812-819.
[28] Shimura S, Watashi K, Fukano K, et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol 2017;66:685–92.
[29] Wang H, Shang X, Wan X, et al. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep 2016;6:38180.
[30] Haag M, Hofmann U, Murdter TE, et al. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na(+)-taurocholate cotransporting polypeptide inhibitor. Anal Bioanal Chem 2015;407:6815–25.
[31] Slijepcevic D, van de Graaf S F J. Bile acid uptake transporters as targets for therapy[J]. Digestive diseases, 2017, 35(3): 251-258.
[32] Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications[J]. Pharm Res, 2007, 24(10): 1803-1823.
[33] Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases[J]. Nat Rev Drug Discov, 2008, 7(8): 678-693.
[34] Yan Y, Allweiss L, Yang D, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerging microbes & infections, 2019, 8(1): 879-894.
[35] Zhang M, Wang F, Chong Y, et al. Liver myofibroblasts from hepatitis B related liver failure patients may regulate natural killer cell function via PGE2. J Transl Med 2014;12:308.
[36] Eloranta ML, Heinonen S, Mononen T, et al. Risk of obstetric cholestasis in sisters of index patients. Clin Genet 2001;60:42–5.
[37] Pan S, Li X, Jiang P, et al. Variations of ABCB4 and ABCB11 genes are associated with primary intrahepatic stones. Mol Med Rep 2015;11:434–46.
[38] Sookoian S, Castano G, Burgueno A, et al. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 2008;48:125–32.
[39] Mullenbach R, Linton KJ, Wiltshire S, et al. ABCB4 gene sequence variation in wmen with intrahepatic cholestasis of pregnancy. J Med Genet 2003;40:e70.
[40] Bacq Y, Gendrot C, Perrotin F, et al. ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. J Med Genet 2009;46:711–5.
[41] Davit-Spraul A, Gonzales E, Jacquemin E. NR1H4 analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations.[J] Clin Res Hepatol Gastroenterol 2012;36:569–73.